{"id":98,"date":"2012-08-21T15:03:39","date_gmt":"2012-08-21T15:03:39","guid":{"rendered":"https:\/\/www.transplantevidence.com\/blog\/?p=98"},"modified":"2012-08-21T15:03:39","modified_gmt":"2012-08-21T15:03:39","slug":"sirolimus-and-secondary-skin-cancer-prevention-in-kidney-transplantation","status":"publish","type":"post","link":"https:\/\/www.transplantevidence.com\/news\/2012\/08\/21\/sirolimus-and-secondary-skin-cancer-prevention-in-kidney-transplantation\/","title":{"rendered":"Sirolimus and secondary skin cancer prevention in kidney transplantation"},"content":{"rendered":"<p>Sylvie Euvrard and her colleagues (<a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1204166\" title=\"NEJM 2012\">New England Journal of Medicine 2012; 367:329<\/a>) have performed a multicentre randomised trial in patients on a calcineurin inhibitor who had developed at least 1 squamous cell cancer of the skin after renal transplantation. Patients were randomised to either continue on the calcineurin inhibitor or to be converted to sirolimus. There was a significant reduction in the occurrence of subsequent squamous cell carcinomas in the two year follow up period but a considerable number of patients on the sirolimus arm had treatment discontinued because of significant adverse events (including pneumonitis). Nevertheless this does provide further evidence that sirolimus does provide a management protocol for patients with squamous cell carcinomas of the skin after renal transplantation but one would have to accept that there is a very definite risk of serious adverse events. Interestingly renal function remained stable in the two groups at the end of two years.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sylvie Euvrard and her colleagues (New England Journal of Medicine 2012; 367:329) have performed a multicentre randomised trial in patients on a calcineurin inhibitor who had developed at least 1 squamous cell cancer of the skin after renal transplantation. Patients were randomised to either continue on the calcineurin inhibitor or to be converted to sirolimus. [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[163],"tags":[195,231,248,263,274,285],"class_list":["post-98","post","type-post","status-publish","format-standard","hentry","category-trials","tag-clinical-research","tag-immunosuppression","tag-malignancy","tag-peter-morris","tag-rct","tag-sirolimus"],"_links":{"self":[{"href":"https:\/\/www.transplantevidence.com\/news\/wp-json\/wp\/v2\/posts\/98","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.transplantevidence.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.transplantevidence.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.transplantevidence.com\/news\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.transplantevidence.com\/news\/wp-json\/wp\/v2\/comments?post=98"}],"version-history":[{"count":0,"href":"https:\/\/www.transplantevidence.com\/news\/wp-json\/wp\/v2\/posts\/98\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.transplantevidence.com\/news\/wp-json\/wp\/v2\/media?parent=98"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.transplantevidence.com\/news\/wp-json\/wp\/v2\/categories?post=98"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.transplantevidence.com\/news\/wp-json\/wp\/v2\/tags?post=98"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}